B Cell Receptor Signaling

Overview

Antigen receptor signalling is the third input — alongside Toll-like Receptor Signaling in B Cells and cytokines (IFN-gamma, IL-21) — that builds DN2 / atypical B cells. It is also the axis on which the literature has been most confused, because “atypical B cells are BCR-hyporesponsive” and “DN2 cells have intact proximal BCR signalling” are both in circulation and appear to contradict each other.

The current best reading from the ingested sources is that the BCR signal must be early and transient, and that continuous BCR engagement actively suppresses the antibody-secreting output. That reframing dissolves much of the apparent contradiction without invoking exhaustion.

Evidence gap. This page was created only after Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation was ingested; before that the wiki had no BCR-signalling content that could support a page. Even now, the wiki has no data on Syk, Lyn, SHP-1, CD79, or the ITIM biology of CD22/CD72/FcγRIIB. Everything below is either a downstream readout or a pathway-analysis prediction.

Key Points from Literature

The signal must be transient — the hardest number in the wiki on this axis

• In reconstructed human cultures, ASCs accumulated only when anti-Ig was present during days 0–3 alone. Anti-Ig throughout the 6 days, or absent entirely, both gave poor ASC recovery (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human in vitro, ≥3 experiments)
• Repeated with SLE patient naive B cells, the effect was large: 2.8% ASCs with continuous anti-Ig, 18% with none, and 49% with anti-Ig restricted to days 0–3 (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, single SLE donor, representative of 2 independent experiments)
• → Continuous BCR engagement is ~17-fold worse than transient for ASC output. This is a positive mechanism, not a defect.

Once formed, DN2 cells no longer need the BCR at all

• Sorted SLE T-bet^hi^ DN2 cells stimulated for 2.5 days with R848 + IFN-γ + IL-21 + IL-2 and no anti-Ig produced ≥50-fold more IgG ASCs than naive B cells, and only 2–3-fold fewer than conventional memory (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, 3 SLE donors)
• The authors describe DN2 cells as “IFN-γ, TLR ligand and antigen programmed primary effectors that can rapidly differentiate in a BCR-signaling independent manner into ASCs following IL-21 exposure”

Proximal signalling is intact, not broken

• DN2 cells express FCRL5 but retain intact proximal BCR signalling, measured as BLNK phosphorylation after anti-IgG stimulation — explicitly contrasted with the functionally exhausted FCRL4⁺ cells of HIV (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, human phospho-flow). This is the wiki’s only positive BCR-proximal measurement.
• Pathway analysis of the DN2 transcriptional network predicted BTK among the upstream regulators, alongside STAT1 and STAT3 (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human RNA-seq, IPA — a prediction, not a measurement)
• Chromatin accessibility around NF-κB p65 and REL motifs — the TFs downstream of BCR and TLR7/8 engagement — was greatest when IFN-γ and IL-2 were also present, indicating cytokine context gates how much BCR/TLR signal reaches the genome (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, ATAC-seq n=2–3/group)
• NR4A1/NR4A3 are used as transcriptional readouts of BCR and TLR engagement (see Scharer2019 - Epigenetic Programming in SLE B Cells, human)

The inhibitory-receptor surface

• DN2 cells carry a CD32b^hi^ CD22^hi^ phenotype (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, human)
• TLR7 stimulation downregulates the inhibitory receptors CD72 and CD32b while upregulating HLA-DR and CD86 (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, human phospho-flow n=5–10)
• DN3 cells are reported as having the lowest CD22, CD72, CD69 and BAFF-R of the DN subsets (see Lamprinou2026 - ABCs and DN B Cells, review). See DN3 B Cell.
• Inhibitory receptors — FcγRIIB, and per the review FCRL5 — must be physically excluded from the B cell immune synapse for BCR signalling and plasma cell differentiation to proceed, which only membrane-associated antigen achieves (see Glaros2025 - Multilayered Identity of B Cell Memory, review, citing Ambegaonkar 2020; the wiki notes the primary abstract names only FcγRIIB, so the FCRL5 attribution is the review’s)

Contradictions & Debates

★ “Hyporesponsive” versus “intact” — is this a real contradiction?

• The HIV/malaria atypical memory literature describes BCR hyporesponsiveness and originally framed these cells as exhausted or anergic. Sanz2019 - Consistent Classification of Human B Cell Populations supports the distinction phenotypically: HIV DN cells are FcRL4⁺FcRL5⁻ whereas SLE DN2 cells are FcRL5⁺FcRL4⁻, and CD11c is high in SLE and not in HIV.
• The SLE DN2 literature reports intact proximal signalling and an activated effector phenotype.
• Reading: these may simply be different cells, as Sanz2019 argues, in which case there is no contradiction to resolve — only a naming collision. The wiki’s exhaustion-was-wrong arc applies to DN2; it may not apply to the HIV FcRL4⁺ cell.
• A second, compatible contributor is the soluble-versus-membrane antigen assay artefact already tracked in this wiki: studies reporting poor differentiation used soluble anti-Ig, which cannot exclude inhibitory receptors from the synapse. Zumaquero2019’s finding that continuous soluble anti-Ig suppresses ASC output ~17-fold is consistent with that artefact being real.

The CD32b^hi^CD22^hi^ paradox. DN2 cells are high for two ITIM-bearing inhibitory receptors yet hyper-responsive to TLR7 and highly primed for ASC differentiation. Partially explained by TLR7-driven downregulation of CD72/CD32b, but the wiki has no ITIM phosphorylation or phosphatase data and cannot resolve it. See Toll-like Receptor Signaling in B Cells.

Related Pages

Toll-like Receptor Signaling in B Cells, IFN-gamma, IL-21, FCRL5, FcRH4, DN2 B Cell, DN3 B Cell, Atypical B Cell, Phospho-Flow Cytometry, In Vitro B Cell Stimulation, Atypical B Cell Effector Output

Sources

• Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation
• Jenks2018 - DN2 B Cells and EF Pathway in SLE
• Scharer2019 - Epigenetic Programming in SLE B Cells
• Glaros2025 - Multilayered Identity of B Cell Memory
• Sanz2019 - Consistent Classification of Human B Cell Populations
• Lamprinou2026 - ABCs and DN B Cells